Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From Forty Seven Inc.

Ichnos’ Early-Stage Myeloma Asset Designed To Avoid ‘Pitfalls’ Of Magrolimab

Glenmark’s innovation subsidiary, Ichnos, highlights encouraging early data for lead bispecific antibody assets and hopes to accelerate these via licensing and partnership deals.The US-based arm also points to the tough biopharma financing market where investors are no longer satisfied with just the “preclinical story”.

Research & Development Clinical Trials

Finance Watch: HilleVax, Belite Bio Launch First Two Biopharma IPOs In Q2

Also, Cytovia will go public via SPAC merger, Nkarta capitalized on its positive early NK cell therapy data with a $230m offering, and venture capital mega-rounds include $220m for Reify, $110m for Satellite Bio and $100m for OMass Therapeutics. 

Financing Innovation

Foresite Sees Plenty Of Investor Interest In Biopharma As It Raises $173m Fund

With its new fund for companies emerging from Foresite Labs, Foresite Capital has raised more than $1bn in new venture capital during the past year to back life science and health care innovation.

Financing Innovation

Ichnos Gets Going With Almirall Deal, Multiple Myeloma Bispecifics Add Sheen

Glenmark’s US-based innovation arm Ichnos delivers first licensing deal for IL-1RAP antagonist, while early data for a bispecific antibody demonstates promising activity in multiple in vitro and in vivo tumor models relative to daratumumab and magrolimab.

Commercial Deals
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
UsernamePublicRestriction

Register